Adaptimmune Therapeutics PLC
(NASDAQ:ADAP)
$0.5273
-0.0176[-3.23%]
Last update: 9:27AM (Delayed 15-Minutes)
Get Real Time Here
$0.5273
0[0.00%]
After-Hours
Open0.522Close0.502
Vol / Avg.427.035K / 429.851KMkt Cap119.761M
Day Range0.495 - 0.53052 Wk Range0.420 - 2.350

Adaptimmune Therapeutics Stock (NASDAQ:ADAP), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Buy

Highest Price Target1

$10.00

Lowest Price Target1

$1.00

Consensus Price Target1

$4.94

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
30010

Analyst Firms Making Recommendations1

  • Barclays
  • EF Hutton
  • Guggenheim
  • Wells Fargo
  • Mizuho

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Adaptimmune Therapeutics

Upgrades (2)

Downgrades (0)

Initiations (2)

date
ticker
Buy Now
Company
Current price
Upside/Downside
Analyst Firm
Analyst & % Accurate
Price Target Change
Rating Change
Previous / Current Rating
Get Alert
08/10/2023ADAPBuy Now
Adaptimmune Therapeutics
$0.5389.65%Barclays
Peter Lawson
$2 → $1MaintainsUnderweightGet Alert
08/10/2023ADAPBuy Now
Adaptimmune Therapeutics
$0.531796.45%EF Hutton
Tony Butler
→ $10ReiteratesBuy → BuyGet Alert
06/05/2023ADAPBuy Now
Adaptimmune Therapeutics
$0.531796.45%EF Hutton
Tony Butler
→ $10ReiteratesBuy → BuyGet Alert
06/02/2023ADAPBuy Now
Adaptimmune Therapeutics
$0.531796.45%EF Hutton
Tony Butler
→ $10Reiterates → BuyGet Alert
05/26/2023ADAPBuy Now
Adaptimmune Therapeutics
$0.531796.45%EF Hutton
Tony Butler
→ $10Reiterates → BuyGet Alert
04/17/2023ADAPBuy Now
Adaptimmune Therapeutics
$0.531796.45%EF Hutton
Tony Butler
→ $10Reiterates → BuyGet Alert
04/11/2023ADAPBuy Now
Adaptimmune Therapeutics
$0.531796.45%EF Hutton
Tony Butler
→ $10Reiterates → BuyGet Alert
03/06/2023ADAPBuy Now
Adaptimmune Therapeutics
$0.531796.45%EF Hutton
Tony Butler
→ $10Reiterates → BuyGet Alert
01/05/2023ADAPBuy Now
Adaptimmune Therapeutics
$0.531796.45%EF Hutton
Tony Butler
→ $10Initiates → BuyGet Alert
01/03/2023ADAPBuy Now
Adaptimmune Therapeutics
$0.53848.23%Guggenheim
Michael Schmidt
→ $5UpgradeNeutral → BuyGet Alert
11/14/2022ADAPBuy Now
Adaptimmune Therapeutics
$0.53468.94%Wells Fargo
Yanan Zhu
$1.5 → $3MaintainsEqual-WeightGet Alert
11/09/2022ADAPBuy Now
Adaptimmune Therapeutics
$0.531606.81%Mizuho
Mara Goldstein
→ $9UpgradeNeutral → BuyGet Alert
10/04/2022ADAPBuy Now
Adaptimmune Therapeutics
$0.53184.47%Wells Fargo
Nick Abbott
$7 → $1.5MaintainsEqual-WeightGet Alert
05/09/2022ADAPBuy Now
Adaptimmune Therapeutics
$0.53468.94%SVB Leerink
Jonathan Chang
$2 → $3MaintainsMarket PerformGet Alert
03/15/2022ADAPBuy Now
Adaptimmune Therapeutics
$0.53468.94%SVB Leerink
Jonathan Chang
$7 → $3MaintainsMarket PerformGet Alert
09/22/2021ADAPBuy Now
Adaptimmune Therapeutics
$0.531227.52%Wells FargoMaintainsEqual-WeightGet Alert
09/13/2021ADAPBuy Now
Adaptimmune Therapeutics
$0.531227.52%SVB Leerink
Jonathan Chang
MaintainsMarket PerformGet Alert
09/07/2021ADAPBuy Now
Adaptimmune Therapeutics
$0.531037.87%SVB Leerink
Jonathan Chang
MaintainsMarket PerformGet Alert
08/10/2021ADAPBuy Now
Adaptimmune Therapeutics
$0.53848.23%SVB Leerink
Jonathan Chang
MaintainsMarket PerformGet Alert
Q

What is the target price for Adaptimmune Therapeutics (ADAP)?

A

The latest price target for Adaptimmune Therapeutics (NASDAQ: ADAP) was reported by Barclays on August 10, 2023. The analyst firm set a price target for $1.00 expecting ADAP to rise to within 12 months (a possible 89.65% upside). 10 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Adaptimmune Therapeutics (ADAP)?

A

The latest analyst rating for Adaptimmune Therapeutics (NASDAQ: ADAP) was provided by Barclays, and Adaptimmune Therapeutics maintained their underweight rating.

Q

When is the next analyst rating going to be posted or updated for Adaptimmune Therapeutics (ADAP)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Adaptimmune Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Adaptimmune Therapeutics was filed on August 10, 2023 so you should expect the next rating to be made available sometime around August 10, 2024.

Q

Is the Analyst Rating Adaptimmune Therapeutics (ADAP) correct?

A

While ratings are subjective and will change, the latest Adaptimmune Therapeutics (ADAP) rating was a maintained with a price target of $2.00 to $1.00. The current price Adaptimmune Therapeutics (ADAP) is trading at is $0.53, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.